MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) has announced that its CEO, Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference. The presentation will be available on demand starting January 10, 2022. Interested individuals can find the webcast link in the Events & Presentations section of the company’s website, where it will remain accessible for 14 days post-event.

The company specializes in inhaled therapeutic products for endocrine and orphan lung diseases, with its flagship product being Afrezza, the only inhaled ultra rapid-acting mealtime insulin in the U.S.

News Market Reaction – MNKD

-3.79%

-3.79% Session move

In the trading session that priced this news, MNKD declined 3.79%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations. The webcast replay may be accessed at the same location for 14 days.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza^® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

FAQ

When will the MannKind Corporation presentation at the H.C. Wainwright Bioconnect Conference be available?

The presentation will be available on demand starting January 10, 2022.

Where can I access the MannKind Corporation webcast of the H.C. Wainwright Bioconnect Conference?

The webcast can be accessed from the Events & Presentations section of MannKind Corporation’s website.

What is Afrezza and who commercializes it?

Afrezza is an inhaled ultra rapid-acting mealtime insulin approved in the U.S. and is commercialized by MannKind Corporation.

What type of products does MannKind Corporation develop?

MannKind Corporation focuses on the development of inhaled therapeutic products for endocrine and orphan lung diseases.

How long will the webcast replay of the MannKind presentation be available?

The webcast replay will be available for 14 days after the presentation.